PortalPublikationenPerspectives on sipuleucel-T: Its role in the prostate cance...

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm

Standard

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. / Gulley, James L; Mulders, Peter; Albers, Peter; Banchereau, Jacques; Bolla, Michel; Pantel, Klaus; Powles, Thomas.

in: ONCOIMMUNOLOGY, Jahrgang 5, Nr. 4, 04.2016, S. e1107698.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gulley, JL, Mulders, P, Albers, P, Banchereau, J, Bolla, M, Pantel, K & Powles, T 2016, 'Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm', ONCOIMMUNOLOGY, Jg. 5, Nr. 4, S. e1107698. https://doi.org/10.1080/2162402X.2015.1107698

APA

Gulley, J. L., Mulders, P., Albers, P., Banchereau, J., Bolla, M., Pantel, K., & Powles, T. (2016). Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. ONCOIMMUNOLOGY, 5(4), e1107698. https://doi.org/10.1080/2162402X.2015.1107698

Vancouver

Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K et al. Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. ONCOIMMUNOLOGY. 2016 Apr;5(4):e1107698. https://doi.org/10.1080/2162402X.2015.1107698

Bibtex

@article{691c8156886745ddbc8c5ab4078c44fd,
title = "Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm",
abstract = "Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, focusing on interpretation and clinical implications. Important differences between immunotherapies and traditional therapies were explored, e.g., mode of action, outcomes, data consistency and robustness, timing of sipuleucel-T treatment, and future perspectives in areas such as short-term markers of long-term benefit.",
author = "Gulley, {James L} and Peter Mulders and Peter Albers and Jacques Banchereau and Michel Bolla and Klaus Pantel and Thomas Powles",
year = "2016",
month = apr,
doi = "10.1080/2162402X.2015.1107698",
language = "English",
volume = "5",
pages = "e1107698",
journal = "ONCOIMMUNOLOGY",
issn = "2162-402X",
publisher = "Taylor & Francis",
number = "4",

}

RIS

TY - JOUR

T1 - Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm

AU - Gulley, James L

AU - Mulders, Peter

AU - Albers, Peter

AU - Banchereau, Jacques

AU - Bolla, Michel

AU - Pantel, Klaus

AU - Powles, Thomas

PY - 2016/4

Y1 - 2016/4

N2 - Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, focusing on interpretation and clinical implications. Important differences between immunotherapies and traditional therapies were explored, e.g., mode of action, outcomes, data consistency and robustness, timing of sipuleucel-T treatment, and future perspectives in areas such as short-term markers of long-term benefit.

AB - Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, focusing on interpretation and clinical implications. Important differences between immunotherapies and traditional therapies were explored, e.g., mode of action, outcomes, data consistency and robustness, timing of sipuleucel-T treatment, and future perspectives in areas such as short-term markers of long-term benefit.

U2 - 10.1080/2162402X.2015.1107698

DO - 10.1080/2162402X.2015.1107698

M3 - SCORING: Journal article

C2 - 27141392

VL - 5

SP - e1107698

JO - ONCOIMMUNOLOGY

JF - ONCOIMMUNOLOGY

SN - 2162-402X

IS - 4

ER -